Aamir Shahzad*, Craig S McLachlan, Judith Gault, Randall J Cohrs, Xiangdong Wang & Gottfried Köhler.
1Department for Biomolecular Structural Chemistry, Max F. Perutz Laboratories, University of Vienna,Austria.
2Rural Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia.
3Department of Psychiatry & Neurosurgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
4Department of Neurology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
5Biomedical Research Center and Department of Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Abstract:
Translational medicine results from collaborations between clinics, research hospitals, governments, academics, and small to large scale industry where diseases (infectious, acquired, or genetic) are identified, candidate therapeutics optimized and tested in cell culture, humanized small animal models, and in clinical trial. The goal of translational medicine is to bring to market safe and effective therapeutics in a timely and cost efficient manner. However, clinician/scientists critically trained in translational research are few and more programs to foster their development are required. Herein the state of translational medicine in leading countries (UK,Netherlands, Austria, Singapore, China, Australia, Japan, India, Malaysia, South Korea and the United States) as well as joint EU efforts is described. A summary of programs, research projects, funding agencies, national support levels and unique opportunities within each nation are presented. The future of translational medicine and interagency collaborations is promising, provided highly trained translational medicine experts can be trained. That is to produce translational leaders that engage the patient, the laboratory, industry and government.
Read More!